We estimate that the CEO of OCULAR THERAPEUTIX, INC ($OCUL), Pravin U. Dugel, received a compensation of $35,946,958 in 2025. This is an increase of 48.33% from an estimated $18,574,830 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 30, 2026. Note that parsing errors may occur.
You can track $OCUL on Quiver Quantitative's $OCUL stock dashboard.
$OCUL Stock Insider Trading Activity
$OCUL Stock insiders have traded $OCUL stock on the open market 13 times in the past 6 months. Of those trades, 1 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 2 sales selling 144,938 shares for an estimated $1,294,996.
- RICHARD L MD LINDSTROM purchased 60,229 shares for an estimated $461,354
- NAMRATA SAROJ (Chief Business Officer) sold 25,865 shares for an estimated $277,790
- DONALD NOTMAN (Chief Operating Officer) has made 0 purchases and 3 sales selling 22,936 shares for an estimated $204,869.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 2 sales selling 12,107 shares for an estimated $108,110.
- NADIA WAHEED (Chief Medical Officer) has made 0 purchases and 2 sales selling 11,373 shares for an estimated $98,248.
- JEFFREY S. HEIER (Chief Scientific Officer) sold 3,057 shares for an estimated $25,311
- PETER KAISER (Chief Development Officer) sold 2,810 shares for an estimated $23,266
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$OCUL Stock Hedge Fund Activity
We have seen 161 institutional investors add shares of $OCUL Stock stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VR ADVISER, LLC removed 5,845,915 shares (-44.4%) from their portfolio in Q4 2025, for an estimated $70,969,408
- BLACKROCK, INC. added 5,045,557 shares (+47.8%) to their portfolio in Q4 2025, for an estimated $61,253,061
- DEEP TRACK CAPITAL, LP removed 3,861,723 shares (-32.4%) from their portfolio in Q4 2025, for an estimated $46,881,317
- POINT72 ASSET MANAGEMENT, L.P. removed 3,585,073 shares (-77.9%) from their portfolio in Q4 2025, for an estimated $43,522,786
- CITADEL ADVISORS LLC removed 3,227,932 shares (-56.6%) from their portfolio in Q4 2025, for an estimated $39,187,094
- VANGUARD GROUP INC added 2,411,953 shares (+26.3%) to their portfolio in Q4 2025, for an estimated $29,281,109
- JANUS HENDERSON GROUP PLC added 2,180,702 shares (+106.5%) to their portfolio in Q4 2025, for an estimated $26,473,722
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
$OCUL Stock Analyst Ratings
Wall Street analysts have issued reports on $OCUL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Clear Street issued a "Buy" rating on 03/03/2026
- Chardan Capital issued a "Buy" rating on 02/18/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for $OCUL Stock, check out Quiver Quantitative's $OCUL forecast page.
$OCUL Stock Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 4 analysts offer price targets for $OCUL in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $21.0 on 04/13/2026
- Bill Maughan from Clear Street set a target price of $28.0 on 03/03/2026
- Serge Belanger from Needham set a target price of $18.0 on 02/20/2026
- Daniil Gataulin from Chardan Capital set a target price of $21.0 on 02/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
